LeMaitre Vascular Inc logo

LeMaitre Vascular Inc(LMAT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 3 days
PROFIT SINCE LAST BUY
-5.95% ▼
LAST CLOSE
$78.29
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LMAT

11/13/2026: LMAT (1-star) is a SELL. SELL for 3 days. Simulated Profits (-5.95%). Updated daily EoD!

LeMaitre Vascular Inc is a medical device company that designs and markets specialized products for vascular surgery. The company benefits from a dedicated direct sales force, high gross margins, and a resilient portfolio anchored by products like the XenoSure patch. Its primary growth strategy revolves around organic market expansion and disciplined tuck-in acquisitions of niche surgical lines. Key risks include revenue concentration, regulatory compliance hurdles, and the gradual shift toward minimally invasive endovascular procedures. The stock suits growth-oriented or moderate-risk investors seeking exposure to specialized medical technology, with ongoing attention required on organic revenue trends and integration milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers steady, reliable organic growth rather than hyper-growth characteristics.
Momentum investorStrong fit while signal remains positiveSuits momentum strategies conditional on a strong upward price trend and positive quarterly earnings surprises.
Value investorMixed fitValuation multiples often reflect consistent profitability, making it less of a classic deep-value play.
Dividend investorMixed fitProvides regular dividend income, though yields are typically modest relative to traditional income stocks.
Low-risk investorMediumExhibits moderate market volatility and solid balance sheet health, though small-cap medical device risk remains.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highAs a smaller-cap medical device stock, shares can experience sharper price swings during broader market corrections.
Valuation riskMediumTrading at premium earnings multiples leaves little room for operational missteps or earnings misses.
Competition risk (large medtech conglomerates)MediumWell-capitalized larger competitors could attempt to encroach on core niche product markets.
Business qualityStrongHigh gross margins and clean balance sheet underscore robust underlying franchise quality.
Dividend incomeLowDividend payouts are safe but yield lower cash return relative to capital appreciation objectives.
Execution riskMediumSuccessful integration of tuck-in acquisitions and new product launches is vital for sustaining long-term growth.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.79B USD
Price to earnings Ratio 28.47
1Y Target Price 99.29
Price to earnings Ratio 28.47
1Y Target Price 99.29
Volume (30-day avg) 281.4K shares
Beta 0.49
52 Weeks Range 77.46 - 117.37
Updated Date 11/15/2026
52 Weeks Range 77.46 - 117.37
Updated Date 11/15/2026
Dividends yield (FY) 1.22%
Basic EPS (TTM) 2.75

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -28.78%
Avg. Invested days 36
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
LMAT receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
LMAT has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and strong ownership. In FY2025 versus FY2024, solid earnings growth (+31.1%) supports the fundamentals score.

Financial Health Rating

★★★★★
LMAT's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 70.2%). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is LMAT's strongest growth driver at +100.4% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+13.5%, solid) and earnings growth (+31.1%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 103.8% and approximately 93.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 8.05% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 14.30%
Conestoga Capital Advisors, LLC 5.98%
First Trust Advisors L.P. 4.78%
Congress Asset Management Company, LLP 4.21%
Vanguard Capital Management, LLC 4.17%

Unit Economics (Per $1K Revenue)

★★★★★
LMAT generates approximately $715 of gross profit, $272 of operating income, and $298 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and strong cash conversion support the rating, although capital efficiency remains soft.

Economic Dimensions

★★★★★
Effective Tax Rate: 23.21%

Quantitative Style Profile

★★★★★
LMAT has a high-quality, liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Quality TiltLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Vascular DevicesSales of biological grafts, patches like XenoSure, shunts, and catheters used primarily in open vascular procedures.This is the primary earnings engine of the company, driven by recurring surgical product demand.
Geographic Operations (North America & International)Direct sales operations spanning the United States, Europe, and Asia Pacific.Geographic diversification helps cushion regional economic downturns and expands the addressable customer base.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-11-04
When After Market
Estimate 0.69
Actual 0.65

Profitability

Profit Margin 23.51%
Operating Margin (TTM) 24.69%

Management Effectiveness

Return on Assets (TTM) 6.63%
Return on Equity (TTM) 15.62%

Valuation

Trailing PE 28.47
Forward PE 24.94
Enterprise Value 1.59B
Price to Sales(TTM) 6.65
Enterprise Value 1.59B
Price to Sales(TTM) 6.65
Enterprise Value to Revenue 5.9
Enterprise Value to EBITDA 16.24
Shares Outstanding 22.88M
Shares Floating 21.31M
Shares Outstanding 22.88M
Shares Floating 21.31M
Percent Insiders 8.05
Percent Institutions 103.81

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.